Most searches for a “GLP-1 medication names list” lead to long tables of brand names, dosing forms, and manufacturers. These lists are thorough, but they rarely help someone make an actual decision. A name on a chart says nothing about whether that option fits a person’s health history, goals, or circumstances.
Clinical providers organize the field differently. They think in categories: groups of options that share a regulatory status, a sourcing model, and a set of clinical considerations. At Red Mountain, providers work within three categories:
- FDA-approved brand-name GLP-1 medications
- Compounded GLP-1 medications
- Red Mountain’s own RM3® program
Understanding these categories makes the landscape far easier to navigate. The choice itself remains a clinical decision made with a provider, not a product picked from a list.
Why “GLP-1” Describes a Category, Not a Single Drug
“GLP-1” refers to a therapeutic class, not one medication. The class spans multiple active ingredients and molecules. Industry trackers count seven or more FDA-approved GLP-1-class medications as of 2026.
The approved uses have also expanded. The class began with diabetes management, grew to include weight management, and now covers additional indications. Weight management has become the fastest-growing segment of the category, while diabetes remains a major use. A static list of names cannot capture a class that keeps changing.
A Note on Mechanism: Single-Receptor vs. Dual-Receptor Agonists
Medications in this class do not all work the same way. Some act on a single incretin hormone receptor (GLP-1). Others, such as tirzepatide, act on two receptors at once: GIP and GLP-1.
This difference in mechanism is one reason providers evaluate each molecule on its own terms rather than treating “GLP-1” as a single interchangeable option. The broadening of approved uses shows the same point: indications within the class now extend beyond diabetes and weight management to include other conditions, such as obstructive sleep apnea in certain adults.
Category One: FDA-Approved Brand-Name GLP-1 Medications
FDA approval has a specific clinical meaning. It indicates that the agency has reviewed a drug’s safety, effectiveness, and manufacturing quality for a defined indication. That review covers the product as manufactured and labeled.
Brand-name GLP-1s like Zepbound fall into this category, alongside other FDA-approved options in the class. Many providers consider this category a natural starting point for patients who are clinical candidates, because of the regulatory review behind these products.
Access and Supply Considerations for Brand-Name GLP-1s
For several years, brand-name GLP-1 supply was limited. That situation has changed. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Brand-name supply has stabilized considerably since then.
This resolved-shortage status matters beyond availability. It is a major reason the regulatory environment around compounding has shifted, as the next section explains.
Category Two: Compounded GLP-1 Medications
Compounding refers to patient-specific formulations prepared by licensed pharmacies. Historically, compounding has filled gaps when brand-name medications were unavailable or when a patient needed a formulation not commercially produced.
Within this category, providers may prescribe compounded GLP-1 medications, which have also frequently included additional ingredients. Industry data shows that more than 80% of these prescriptions historically included supplemental ingredients such as B-vitamins or L-carnitine. In practice, “compounded” has often meant an altered formulation rather than a simple copy of a brand-name product.
The 2026 Regulatory Shift Away From Mass Compounding
From 2022 through 2025, a drug-shortage exception allowed broad compounding of these medications. The exception was a temporary regulatory provision tied to the officially declared drug shortages.
With the shortages resolved, the legal basis for mass compounding has narrowed. On April 30, 2026, the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding “no clinical need for outsourcing facilities to compound these drugs from bulk drug substances.”
FDA guidance clarifies that 503A state-licensed pharmacies may still compound patient-specific versions in narrow circumstances with documented clinical necessity. Broad, mass-scale compounding, however, is being phased out.
Throughout 2026, the FDA also issued waves of warning letters to telehealth companies over misleading claims about compounded GLP-1 products: more than 30 in one round, followed by 25 more. This enforcement shows why clinical oversight and accurate communication matter so much in this category.
Safety Context Behind the Crackdown
The increased scrutiny rests on documented concerns. By May 2026, the FDA had logged roughly 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide.
Formulation itself is part of the concern. A 2026 study found that compounding tirzepatide with B12 can cause the two substances to chemically bond, forming a new molecule that has not been studied.
Regulatory status and oversight differ meaningfully across the three categories. That context is part of what Red Mountain’s providers discuss directly with patients when reviewing this category.
Category Three: Red Mountain’s RM3 Program
The third category is specific to Red Mountain. RM3® is a proprietary oral tablet formulation, taken twice daily. It is distinct from GLP-1 injectables.
RM3 is sourced independently. As a result, it is not subject to the same shortage dynamics that have affected brand-name GLP-1 products.
RM3 is not positioned as a replacement for, or an equivalent to, any GLP-1 medication, branded or compounded. It is a separate clinical pathway that some patients and providers may consider. It also reflects the depth of Red Mountain’s history: the RM3 legacy is the product of more than 30 years of clinical refinement and real-world patient experience, not a recent addition assembled to follow a trend.
How Providers Actually Choose Between the Three Categories
A provider choosing among these categories weighs several clinical factors:
- Health history, including existing conditions and current medications
- Prior medication response, including side effects and tolerance
- Goals, such as metabolic health, energy, and long-term maintenance
- Risk tolerance and the patient’s comfort with each category’s regulatory status
- Access and supply realities at the time of treatment
Medication selection is only one part of a supervised plan. At Red Mountain, that plan also includes monitoring, nutrition strategy, and support designed to help minimize side effects, preserve muscle mass, and maintain nutrient balance.
The medication is a tool. Structure, support, and clinical guidance are what sustain results over time. This is exactly why a list of names cannot answer the question a patient actually has: which category, and which option within it, fits their situation and can be appropriately monitored.
The Growing GLP-1 Landscape: Why Category Thinking Matters More Than Ever
Use of these medications has grown quickly. According to Gallup, about 11% of US adults were taking a GLP-1 drug for weight loss by mid-2026, up from roughly 3% in 2024. Market analyses place the global category among the largest in the pharmaceutical industry, with continued growth projected over the next decade.
That growth means more active ingredients, formulations, and indications are likely to emerge. Any brand list will keep going out of date. Knowing how to categorize and evaluate options is the more durable skill.
Conclusion: Thinking Like a Provider, Not a Shopper
The three-category framework brings order to a crowded field:
- FDA-approved brand-name GLP-1s, with Zepbound as one example
- Compounded GLP-1s, a category now narrowing under 2026 FDA policy
- Red Mountain’s proprietary RM3 program, a distinct oral pathway
The useful question is not “which name is best.” It is “which category and option fits this health profile, under proper supervision.” Within Red Mountain’s approach, medication is one tool inside a long-term plan for metabolic correction, guided by decades of clinical experience.
Next Step: Talk Through Your Options With a Provider
For anyone sorting through these categories, a consult is usually the next step. It is the setting where health history, goals, and the available options are reviewed together. A consult is not a commitment; it is a conversation.
Red Mountain’s providers explain each category in plain terms and build a plan around the whole person. The practice serves as a clinically-led partner for the full journey, from establishing a metabolic foundation through long-term maintenance, rather than as a single-product provider.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.
